PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value
$63.49+0.13 (+0.21%)
Close on Nov 13, 2026Market cap $5.30BP/E –Yield –
PTC Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
PTC Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was $208.71M, down 74.2% year over year. For fiscal 2025 it was $905.75M. The highest annual figure on record is $905.75M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $905.75M | – |
| FY2024 | Dec 31, 2024 | -$226.91M | – |
| FY2023 | Dec 31, 2023 | -$202.91M | – |
| FY2022 | Dec 31, 2022 | -$318.57M | – |
| FY2021 | Dec 31, 2021 | -$310.31M | – |
| FY2020 | Dec 31, 2020 | -$388.28M | – |
| FY2019 | Dec 31, 2019 | -$208.98M | – |
| FY2018 | Dec 31, 2018 | -$89.60M | – |
| FY2017 | Dec 31, 2017 | -$46.61M | – |
| FY2016 | Dec 31, 2016 | -$128.77M | – |
| FY2015 | Dec 31, 2015 | -$164.25M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $41.93M | +196.9% |
| Q2 FY2026 | Jun 30, 2026 | $164.85M | – |
| Q1 FY2026 | Mar 31, 2026 | $60.37M | -93.8% |
| Q4 FY2025 | Dec 31, 2025 | -$58.45M | – |
| Q3 FY2025 | Sep 30, 2025 | $14.13M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.37M | – |
| Q1 FY2025 | Mar 31, 2025 | $977.45M | +9731.5% |
| Q4 FY2024 | Dec 31, 2024 | -$155.63M | -279.9% |
| Q3 FY2024 | Sep 30, 2024 | -$48.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.20M | – |
| Q1 FY2024 | Mar 31, 2024 | $9.94M | – |
| Q4 FY2023 | Dec 31, 2023 | $86.53M | – |
| Q3 FY2023 | Sep 30, 2023 | -$56.11M | – |
| Q2 FY2023 | Jun 30, 2023 | -$158.54M | – |
| Q1 FY2023 | Mar 31, 2023 | -$74.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$161.48M | – |
| Q3 FY2022 | Sep 30, 2022 | -$33.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$63.18M | – |
| Q1 FY2022 | Mar 31, 2022 | -$60.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$65.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$76.33M | – |
| Q2 FY2021 | Jun 30, 2021 | -$83.51M | – |
| Q1 FY2021 | Mar 31, 2021 | -$84.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$83.97M | – |
| Q3 FY2020 | Sep 30, 2020 | -$43.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$177.06M | – |
| Q1 FY2020 | Mar 31, 2020 | -$83.76M | – |
See a number that looks wrong?